Eli Lilly reports revenue up 39% and raises full-year guidance

Lilly said third-quarter revenue rose 39% to $24.4 billion and that earnings per share were $7.22 on a reported basis, or $7.48 on a non-GAAP basis. It raised its 2026 revenue guidance to a range of $91.0 billion to $92.0 billion. Chair and chief executive David A. Ricks said: "Revenue growth was driven by broad global consumer demand for Mounjaro and Zepbound".